Last Updated : Monday, April 8, 2019 14:41:34

Zydus Cadila (Healthcare) gets USFDA nod to market anti-epileptic drug to prevent & control seizures

AHMEDABAD-GANDHINAGAR | MUMBAI | RAJKOT – In a press-release submitted to the Indian Bourses on Monday, Ahmedabad headquartered pharma major – Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) has received the tentative approval from the USFDA to market Lacosamide Tablets (US RLD – Vimpat®) in the strengths of 50 mg, 100 mg, 150 mg and 200 mg.

Lacosamide is an anticonvulsant or antiepileptic drug, used to prevent and control seizures.

It works by reducing the spread of seizure activity in the brain.

The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has 261 approvals and has so far filed over 350 ANDAS since the commencement of the filing process in FY 2003-04.

For more details, please click the link, given here :


FacebookGoogle+LinkedinTwitterYouTube, Blogspot, Telegram, Instagram 


Do NOT follow this link or you will be banned from the site!